Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00424528
Other study ID # 091-902
Secondary ID
Status Completed
Phase Phase 4
First received January 17, 2007
Last updated May 29, 2012
Start date December 2006
Est. completion date October 2007

Study information

Verified date May 2012
Source Sunovion
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate and compare the efficacy of arformoterol twice a day and tiotropium once a day (dosed sequentially) versus tiotropium once a day alone in subjects with Chronic Obstructive Pulmonary Disease (COPD).


Description:

This study is a multicenter, randomized, modified-blind, double-dummy two-week parallel-group efficacy and safety study of arformoterol tartrate inhalation solution twice daily, tiotropium inhalation powder once daily and arformoterol tartrate inhalation solution twice daily and tiotropium inhalation powder once daily (dosed sequentially) in subjects with COPD. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.


Recruitment information / eligibility

Status Completed
Enrollment 235
Est. completion date October 2007
Est. primary completion date October 2007
Accepts healthy volunteers No
Gender Both
Age group 45 Years and older
Eligibility Inclusion Criteria:

- Male and female subjects must be at least 45 years old at the time of consent.

- Subjects must have a pre-established primary clinical diagnosis of COPD.

- Subjects must have a baseline FEV1 of =65% of predicted normal value at Visit 1.

- Subjects must have a FEV1 = 0.70L at Visit 1.

Exclusion Criteria:

- Subjects who do not have a FEV1/forced vital capacity (FVC) ratio of =70% at Visit 1.

- Subjects who do not have a ³15 pack-year smoking history and a baseline breathlessness severity grade of ³2 (Modified Medical Research Council [MMRC] Dyspnea Scale Score) at Visit 1.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Arformoterol Tartrate Inhalation Solution
Arformoterol tartrate inhalation solution 15 mcg twice daily and placebo inhalation powder once daily.
Tiotropium
Placebo inhalation solution twice daily and tiotropium inhalation powder 18 mcg once daily.
Arformoterol and Tiotropium
Arformoterol tartrate inhalation solution 15 mcg twice daily and Tiotropium inhalation powder 18 mcg once daily.
Placebo
Placebo inhalation solution and placebo inhalation powder

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sunovion

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time-normalized Area Under the Change From Study Baseline Curve for Forced Expiratory Volume in One Second (FEV1) Over 24 Hours (nAUC0-24B) 24 hours following two weeks of dosing. No
Secondary Time-normalized Area From Study Baseline Curve for FEV1 Over 0-12 Hours (nAUC0-12B) 0-12 hours following two weeks of dosing No
Secondary Time Normalized Area Under the Change From Study Baseline Curve for FEV1 Over 12-24 Hours (nAUC12-24B) Following 2 weeks of dosing No
Secondary Change in FEV1 From Study Baseline to the 24-hour Timepoint (Trough) Trough FEV1 is defined as the measurement collected approximately 24 hours after the first in-clinic double-blind dose at Week 0. Change is calculated as Week 2 24 hour post first dose FEV1 - Week 0 pre-first dose FEV1. Following 2 weeks of dosing No
Secondary Change in FEV1 From Study Baseline at Each Assessed Timepoint Post First Dose of Study Medication Baseline is FEV1 measurement collected prior to the first double-blind dose at week 0. Change defined as Week 0 FEV1 - Week 2 pre first dose FEV1. 2 weeks No
Secondary Change in FEV1 Percent of Predicted From Study Baseline at Each Assessed Timepoint Post First Dose of Study Medication Baseline is FEV1 collected prior to first double-blind dose at week 0. Change is defined as Week 0 FEV1 percent predicted - Week 2 pre first dose FEV1 percent predicted. 2 weeks No
Secondary Peak Change in FEV1 Over 12 Hours Post Dose From Study Baseline 12 hour peak change in FEV1 is defined as maximum of the post dose changes through the nominal 12 hour assessment. 2 weeks No
Secondary Time to Onset in Participants Who Achieved a 10% Increase in FEV1 From Visit Predose After 2 Weeks Analyzed from end of dosing to 12 hours. 2 weeks No
Secondary Time to Onset in Participants Who Achieved a 15% Increase in FEV1 From Visit Predose After 2 Weeks Analyzed from end of dosing to 12 hours. 2 weeks No
Secondary Change in Inspiratory Capacity From Study Baseline to the 24 Hour Timepoint (Trough) Following 2 Weeks of Dosing Trough Inspiratory Capacity is defined as the measurement collected approximately 24 hours after the first in clinic double-blind treatment dose at week 0. Change is calculated as Week 2 24 hr post dose IC - Week 0 pre first dose IC. 2 weeks No
Secondary Change in Forced Vital Capacity (FVC) From Study Baseline at Each Assessed Post Dose Timepoint 2 Weeks No
Secondary Levalbuterol Metered Dose Inhaler (MDI) (Rescue Medication) Use in Days Per Week Overall: Average of the levalbuterol usage in days per week over the 2 week period. Mean number of days/week=number of days levalbuterol used during time period, divided by number of days in the period, multiplied by 7. An actuation is one puff of levalbuterol. 2 weeks No
Secondary Levalbuterol Metered Dose Inhaler (MDI) Rescue Medication Use in Actuations Per Day Overall: Average of the usage in number of actuations per day over the 2 week period. An actuation is one puff of levalbuterol. Mean number of actuations/day=number actuations used during time period, divided by number of days in time period. 2 weeks No
Secondary Transition Dyspnea Index (TDI) Focal Score TDI Focal score (range -9 to 9) is defined as the sum of function impairment, magnitude of task, and magnitude of effort (each on a -3 to 3 scale). A score of -9 is maximum worsening and 9 is maximum improvement. 2 weeks No
Secondary Number of Participants With a >= 1 Unit of Improvement in the TDI Focal Score A Greater than or Equal to 1 unit of Improvement in the TDI Focal Score is considered to be clinically important. 2 weeks No
Secondary Percentage of Participants With a >=1 Unit Improvement in Transition Dysnea Index (TDI) Focal Score A Greater than or Equal to 1 unit of Improvement in the TDI Focal Score is considered to be clinically important. 2 weeks No
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy